|
2022-07-01 |
2022-07-01 |
S
Venta
|
Chief Business Officer
Oficial
|
12 937
-23.5%
259,96
3.931.521 US$
|
12 937
-23.5%
|
259,96
|
3.931.521 US$
|
|
|
2022-05-31 |
2022-05-27 |
S
Venta
|
Chief Accounting Officer
Oficial
|
56 282
+21.9%
289,13
1.671.451 US$
|
56 282
+21.9%
|
289,13
|
1.671.451 US$
|
|
|
2022-02-22 |
2022-02-18 |
S
Venta
|
President and CEO
Consejero ejecutivo
|
40 214
+43.4%
340,93
4.488.023 US$
|
40 214
+43.4%
|
340,93
|
4.488.023 US$
|
|
|
2019-12-30 |
2019-12-26 |
S
Venta
|
Krol Patrick Johan Hendrik
Gran accionista
|
81 162
-4.4%
5,24
425.289 US$
|
81 162
-4.4%
|
5,24
|
425.289 US$
|
|
|
2019-11-26 |
2019-11-19 |
B
Compra
|
Krol Patrick Johan Hendrik
Gran accionista
|
2 544
+0.1%
2,79
7.098 US$
|
2 544
+0.1%
|
2,79
|
7.098 US$
|
|
|
2018-12-18 |
2018-12-14 |
S
Venta
|
Shearman Mark S
Chief Scientific Officer
Oficial
|
3 000
-100.0%
3,35
10.053 US$
|
3 000
-100.0%
|
3,35
|
10.053 US$
|
|
|
2018-12-18 |
2018-12-14 |
B
Compra
|
Washer Susan B.
President and CEO
Consejero ejecutivo
|
2 380
+11.7%
3,34
7.949 US$
|
2 380
+11.7%
|
3,34
|
7.949 US$
|
|
|
2018-12-18 |
2018-12-14 |
B
Compra
|
Rosen James
Consejero no ejecutivo
|
1 000
+inf%
3,38
3.381 US$
|
1 000
+inf%
|
3,38
|
3.381 US$
|
|
|
2018-12-18 |
2018-12-14 |
B
Compra
|
Sullivan William A.
Chief Financial Officer
Oficial
|
3 000
+inf%
3,33
9.990 US$
|
3 000
+inf%
|
3,33
|
9.990 US$
|
|
|
2018-12-18 |
2018-12-14 |
B
Compra
|
Aliski William
Consejero no ejecutivo
|
500
+6.2%
3,24
1.620 US$
|
500
+6.2%
|
3,24
|
1.620 US$
|
|
|
2018-12-18 |
2018-12-14 |
B
Compra
|
Aliski William
Consejero no ejecutivo
|
4 300
+116.2%
3,25
13.975 US$
|
4 300
+116.2%
|
3,25
|
13.975 US$
|
|
|
2018-12-18 |
2018-12-14 |
B
Compra
|
Aliski William
Consejero no ejecutivo
|
1 200
+48.0%
3,24
3.882 US$
|
1 200
+48.0%
|
3,24
|
3.882 US$
|
|
|
2016-11-17 |
2016-11-16 |
B
Compra
|
Magovcevic Ivana
Consejero no ejecutivo
|
3 000
+inf%
9,63
28.875 US$
|
3 000
+inf%
|
9,63
|
28.875 US$
|
|
|
2016-11-02 |
2016-11-01 |
Por favor
Venta prevista
|
Chulay Jeffrey D.
VP and Chief Medical Officer
Oficial
|
1 000
-4.7%
7,05
7.052 US$
|
1 000
-4.7%
|
7,05
|
7.052 US$
|
|
|
2016-09-26 |
2016-09-22 |
B
Compra
|
Shearman Mark S
Chief Scientific Officer
Oficial
|
1 300
+76.5%
8,87
11.531 US$
|
1 300
+76.5%
|
8,87
|
11.531 US$
|
|
|
2016-09-26 |
2016-09-22 |
B
Compra
|
Shearman Mark S
Chief Scientific Officer
Oficial
|
1 700
+inf%
8,87
15.070 US$
|
1 700
+inf%
|
8,87
|
15.070 US$
|
|
|
2016-09-27 |
2016-09-20 |
B
Compra
|
Potter Stephen W
See Remarks
Oficial
|
400
+40.0%
8,69
3.476 US$
|
400
+40.0%
|
8,69
|
3.476 US$
|
|
|
2016-09-20 |
2016-09-19 |
B
Compra
|
BULLOCK LAWRENCE E
Chief Financial Officer
Oficial
|
10 000
+inf%
8,75
87.500 US$
|
10 000
+inf%
|
8,75
|
87.500 US$
|
|
|
2016-09-27 |
2016-09-16 |
B
Compra
|
Potter Stephen W
See Remarks
Oficial
|
1 000
+inf%
8,97
8.970 US$
|
1 000
+inf%
|
8,97
|
8.970 US$
|
|
|
2015-02-24 |
2015-02-23 |
S
Venta
|
GLAXOSMITHKLINE PLC
|
503 150
-25.9%
22,00
11.069.602 US$
|
503 150
-25.9%
|
22,00
|
11.069.602 US$
|
|
|
2015-01-26 |
2015-01-23 |
S
Venta
|
Menichella Daniel L
V.P. & Chief Business Officer
Oficial
|
1 996
-100.0%
24,90
49.700 US$
|
1 996
-100.0%
|
24,90
|
49.700 US$
|
|
|
2014-12-23 |
2014-12-22 |
S
Venta
|
Menichella Daniel L
V.P. & Chief Business Officer
Oficial
|
9 000
-100.0%
20,83
187.470 US$
|
9 000
-100.0%
|
20,83
|
187.470 US$
|
|
|
2015-02-12 |
2014-12-18 |
S
Venta
|
GLAXOSMITHKLINE PLC
Gran accionista
|
12 000
-0.6%
21,01
252.136 US$
|
12 000
-0.6%
|
21,01
|
252.136 US$
|
|
|
2015-02-12 |
2014-12-17 |
S
Venta
|
GLAXOSMITHKLINE PLC
Gran accionista
|
8 000
-0.4%
21,00
168.000 US$
|
8 000
-0.4%
|
21,00
|
168.000 US$
|
|
|
2015-02-12 |
2014-12-12 |
S
Venta
|
GLAXOSMITHKLINE PLC
Gran accionista
|
7 500
-0.4%
21,24
159.294 US$
|
7 500
-0.4%
|
21,24
|
159.294 US$
|
|
|
2015-02-12 |
2014-12-11 |
S
Venta
|
GLAXOSMITHKLINE PLC
Gran accionista
|
12 500
-0.6%
21,28
266.035 US$
|
12 500
-0.6%
|
21,28
|
266.035 US$
|
|
|
2015-02-12 |
2014-12-10 |
S
Venta
|
GLAXOSMITHKLINE PLC
Gran accionista
|
10 000
-0.5%
21,18
211.760 US$
|
10 000
-0.5%
|
21,18
|
211.760 US$
|
|
|
2014-04-02 |
2014-04-01 |
B
Compra
|
GLAXOSMITHKLINE PLC
Gran accionista
|
103 762
+5.5%
12,00
1.245.144 US$
|
103 762
+5.5%
|
12,00
|
1.245.144 US$
|
|
|
2014-04-01 |
2014-04-01 |
B
Compra
|
Rosen James
Consejero no ejecutivo
Gran accionista
|
62 871
+5.5%
12,00
754.452 US$
|
62 871
+5.5%
|
12,00
|
754.452 US$
|
|
|
2014-04-01 |
2014-04-01 |
B
Compra
|
MedImmune Ventures, Inc.
Gran accionista
|
75 735
+5.5%
12,00
908.820 US$
|
75 735
+5.5%
|
12,00
|
908.820 US$
|
|
|
2014-04-01 |
2014-04-01 |
B
Compra
|
INTERWEST PARTNERS VIII LP
Gran accionista
|
75 376
+5.5%
12,00
904.512 US$
|
75 376
+5.5%
|
12,00
|
904.512 US$
|
|
|
2014-04-01 |
2014-04-01 |
B
Compra
|
Alta Partners VIII, L.P.
Gran accionista
|
155 645
+5.5%
12,00
1.867.740 US$
|
155 645
+5.5%
|
12,00
|
1.867.740 US$
|
|
|
2014-04-01 |
2014-04-01 |
B
Compra
|
Wu Samuel
Consejero no ejecutivo
Gran accionista
|
75 735
+5.5%
12,00
908.820 US$
|
75 735
+5.5%
|
12,00
|
908.820 US$
|
|
|
2014-04-01 |
2014-04-01 |
B
Compra
|
Carroll Jill
Consejero no ejecutivo
Gran accionista
|
103 762
+5.5%
12,00
1.245.144 US$
|
103 762
+5.5%
|
12,00
|
1.245.144 US$
|
|
|
2014-04-01 |
2014-04-01 |
B
Compra
|
ORONSKY ARNOLD L
Consejero no ejecutivo
Gran accionista
|
75 736
+5.5%
12,00
908.832 US$
|
75 736
+5.5%
|
12,00
|
908.832 US$
|
|